The approval of BRAF inhibitors (BRAFi) marked a pivotal advancement in melanoma therapeutics,128, 129 yet the clinical benefit of these therapies is often transient, with resistance typically emerging within 6 months due to adaptive reactivation of critical oncogenic signaling cascades, particularly the MAPK/ERK130 and PI3K/AKT pathways.131. Here, AKT1 is linked to melanoma.